Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Control (functional) | = 973 % | The compound (10 mg/kg) administered perorally was tested for its ability to augment IL-10 in LPS-stimulated mice | ChEMBL. | 10853651 |
Control (functional) | = 973 % | The compound (10 mg/kg) administered perorally was tested for its ability to augment IL-10 in LPS-stimulated mice | ChEMBL. | 10853651 |
Inhibition (functional) | = 85 % | Inhibit tumour necrosis factor alpha production in LPS-stimulated mice after peroral administration of 10 mg/kg | ChEMBL. | 10853651 |
Inhibition (functional) | = 85 % | Inhibit tumour necrosis factor alpha production in LPS-stimulated mice after peroral administration of 10 mg/kg | ChEMBL. | 10853651 |
logP (ADMET) | = 1.45 | Partition coefficient (logP) | ChEMBL. | 10853651 |
Therapeutic effect (functional) | = 144 % | The compound (10 mg/kg) was tested for its therapeutic effect in an adjuvant-induced arthritis rat | ChEMBL. | 10853651 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.